Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials.
Donald StullSean O'QuinnBetsy WilliamsStephanie BeanErik SchwetjeGabriel AbreuRaj TummalaPublished in: Rheumatology (Oxford, England) (2022)
Anifrolumab is associated with significant patient-reported improvements in aspects of HRQoL including pain, fatigue, mood and physical function. These benefits are from the direct effect of anifrolumab treatment on disease activity and reduction in glucocorticoid dosage.
Keyphrases
- disease activity
- patient reported outcomes
- patient reported
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- sleep quality
- chronic pain
- juvenile idiopathic arthritis
- bipolar disorder
- pain management
- neuropathic pain
- replacement therapy
- spinal cord
- combination therapy
- smoking cessation